Published by Josh White on 16th January 2025
(Sharecast News) - Avacta Therapeutics announced promising results from its ongoing phase 1a trial of AVA6000 on Thursday, demonstrating meaningful tumour shrinkage in patients with salivary gland cancer (SGC).
URL: http://www.digitallook.com/dl/news/story/34817260/...